Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

• Hlavní autoři: Navita L. Mallalieu (Autor), Sunethra Wimalasundera (Autor), Joy C. Hsu (Autor), Wendy Douglass (Autor), Chris Wells (Autor), Inmaculada Calvo Penades (Autor), Ruben Cuttica (Autor), Hans-Iko Huppertz (Autor), Rik Joos (Autor), Yukiko Kimura (Autor), Diana Milojevic (Autor), Margalit Rosenkranz (Autor), Kenneth Schikler (Autor), Tamas Constantin (Autor), Carine Wouters (Autor)
• Médium: Kniha
• Vydáno: BMC, 2019-08-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Background The anti-interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized controlled phase 3 trial. Tocilizumab treatme...